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Abstract
Background: Optimum patient care in relation to labora-
tory medicine is achieved when results of laboratory tests 
are equivalent, irrespective of the analytical platform used 
or the country where the laboratory is located. Standardi-
zation and harmonization minimize differences and the 
success of efforts to achieve this can be monitored with 
international category 1 external quality assessment 
(EQA) programs.
Methods: An EQA project with commutable samples, tar-
geted with reference measurement procedures (RMPs) 
was organized by EQA institutes in Italy, the Netherlands, 
Portugal, UK, and Spain. Results of 17 general chemis-
try analytes were evaluated across countries and across 
manufacturers according to performance specifications 
derived from biological variation (BV).
Results: For K, uric acid, glucose, cholesterol and high-
density density (HDL) cholesterol, the minimum perfor-
mance specification was met in all countries and by all 
manufacturers. For Na, Cl, and Ca, the minimum perfor-
mance specifications were met by none of the countries 
and manufacturers. For enzymes, the situation was com-
plicated, as standardization of results of enzymes toward 
RMPs was still not achieved in 20% of the laboratories and 
questionable in the remaining 80%.
Conclusions: The overall performance of the measure-
ment of 17 general chemistry analytes in European 
medical laboratories met the minimum performance 
specifications. In this general picture, there were no 
significant differences per country and no significant 
differences per manufacturer. There were major differ-
ences between the analytes. There were six analytes for 
which the minimum quality specifications were not met 
and manufacturers should improve their performance 
for these analytes. Standardization of results of enzymes 
requires ongoing efforts.
Keywords: commutability; external quality assessment; 
general chemistry; reference measurement procedures; 
total terror.
Introduction
Results between different laboratories should be equiva-
lent, within clinically meaningful limits, and irrespec-
tive of analytical platforms used, or country in which 
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the laboratory is located [1, 2]. This warrants the basis 
for uniform clinical decisions for the diagnosis and 
monitoring of patients, and ultimately enables optimum 
patient care from perspective of the medical laboratory. 
Absence of confusion on reference intervals and deci-
sion limits is appreciated by clinicians and strengthens 
the professional position of laboratory medicine [3]. 
Standardization and harmonization efforts minimize dif-
ferences between laboratories and are the core issues of 
the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) and the American Associa-
tion of Clinical Chemistry (AACC) [4, 5]. External quality 
assessment (EQA)/proficiency test (PT) organizers play 
an important role in monitoring the performance of indi-
vidual laboratories, but also in supplying information on 
the progress of standardization/harmonization efforts 
[6–9]. In a recent review, EQA/PT schemes are catego-
rized on basis of three characteristics: (a) commutability 
of the samples, (b) value assignment of targets (with a 
RMP or not), and (c) inclusion of replicate samples (yes 
or no) [10]. Optimum information is provided with cat-
egory-1 programs with commutable replicate samples 
having values assigned with RMPs. This paper describes 
the results of such a program organized as a joint project 
by the national EQA organizers in Italy, the Netherlands, 
Portugal, UK, and Spain (“INPUtS” project; INPUtS 
derived from the initials in capitals of the five countries 
and t to make a readable word and to express that all 
countries had “input” in this project) and is the exten-
sion of a previous pilot [11]. Performances of the labo-
ratories are evaluated, both across countries and across 
analytical platforms of major manufacturers and inter-
preted according to specifications derived from biologi-
cal variation (BV) [12]. The study therefore attempts to 
address the following questions: “Was there a difference 
in performance between countries X and Y?”, “Was there 
a difference in performance between the analytical plat-
forms of manufacturers A and B?”, and also “Was it fea-
sible to share commutable samples by five national  EQA 
organizers?”
Materials and methods
Samples
Each laboratory received a set of six commutable frozen human 
serum samples, regularly used in the national EQA program and 
manufactured by the Stichting Kwaliteitsbewaking Medische Labo-
ratoria (SKML; Dutch EQA organization). Samples were shipped on 
dry ice and stored by the laboratories below −70 °C (or, when assayed 
within 2 weeks, at −20 °C). Samples were thawed at room tempera-
ture and analyzed within 8  h after thawing. All target values were 
assigned with reference measurement procedures (RMP). Prepara-
tion, commutability and stability of the samples have been demon-
strated and described in previous publications [11, 13]. Table 1 shows 
the analytes included and their concentration range.
Table 1: Analytes, sample characteristics, biological variation, and total allowable error.
Analyte  
 
Concentration 
 
Biological 
variation, %
 
 
Total allowable error, %
Range  Units CVI  CVG Optimum  Desirable  Minimum
K   4.1–7.2  mmol/L  4.6  5.6  2.8  5.6  8.4
Na   128–163  mmol/L  0.6  0.7  0.4  0.7  1.1
Cl   88–112  mmol/L  1.2  1.5  0.7  1.5  2.2
Ca   2.02–2.84  mmol/L  2.1  2.5  1.3  2.6  3.8
Mg   0.8–1.7  mmol/L  3.6  6.4  2.4  4.8  7.2
Uric acid   0.26–0.50  mmol/L  8.6  17.5  5.9  11.8  17.7
Glucose   6.6–23.4  mmol/L  5.6  7.5  3.5  7.0  10.5
Total protein   55–78  g/L   2.8  4.7  1.8  3.7  5.6
Cholesterol   4.1–6.0  mmol/L  6.0  15.3  4.5  9.0  13.5
HDL-cholesterol   1.1–1.2  mmol/L  7.3  21.2  5.8  11.6  17.4
Amylase   89–240  U/La   8.7  28.3  7.3  14.6  21.9
ASAT   47–131  U/La   12.3  23.1  8.4  16.7  25.0
ALAT   56–147  U/La   19.4  41.6  13.8  27.5  41.2
CK   146–388  U/La   22.8  40.0  15.2  30.3  45.5
GGT   44–140  U/La   13.4  42.1  11.0  22.1  33.2
AP   119–304  U/La   6.4  26.1  6.0  12.0  18.0
LD   226–901  U/La   8.6  14.7  5.7  11.4  17.1
aMeasured with the respective IFCC reference measurement procedures. CVI, within-subject variation; CVG, between-subject variation.
Unauthenticated
Download Date | 1/10/17 5:14 PM
Weykamp et al.: Analytical performance of general chemistry methods      205
Table 2: Number of participants per country and per manufacturer.
Manufacturer   ES  IT  PT  UK  Total ES-IT-
PT-UK
  NL
Abbott Architect   2  6  3  4  15  17
Beckman Coulter Olympus   5  6  3  5  19  8
Beckman Coulter UniCel DxC  1  7  0  0  8  32
Roche Cobas   7  7  8  8  30  139
Siemens Advia   2  0  3  3  8  5
Siemens Dimension   2  6  2  0  10  11
Total   19  32  19  20  90  212
Participants
Table 2 shows the number of participating laboratories specified per 
country and per manufacturer. The laboratories of Italy, Spain, Portu-
gal, and UK were randomly selected by the respective EQA organizers 
but with the criterion to achieve a number of 20–30 per country and 
to cover the common analytical platforms; samples were analyzed in 
addition to the respective regular EQA programs. In the Netherlands, 
the samples were part of the regular EQA program and thus analyzed 
by all laboratories. The analytical platforms of the manufacturers 
with comparable technology were considered as a group, leading to 
one group for Roche (all Cobas instruments) and Abbott (all Archi-
tect models), and to two groups for Beckman-Coulter (UniCel-DxC 
and Olympus AU instruments) and Siemens (Dimension and Advia 
instruments).
Calculations at analyte level
For each sample and each group (group = all laboratories, all labo-
ratories of a country, or all laboratories using the platforms of the 
same manufacturer), the bias of the mean of that group (bias = mean 
of the group – target established with the RMP), and the between-
laboratory coefficient of variation (CV) were calculated. From these, 
the mean bias (B) and mean between-laboratory CV (CVm) of the six 
samples were calculated and used to calculate the total error (TE) of 
the group according to TE = |B|+2 CVm [14]. TEs were compared with 
the total allowable error (TAE) calculated on basis of the BV taken 
from the BV specifications database by Ricós et al. [15] and classified 
as meeting the optimum, desirable, or minimum specification (or as 
not meeting any of the three criteria). BVs and TAEs are summarized 
in Table 1. In addition to the results of the individual countries, these 
calculations were also made for the Italian, Spanish, Portuguese, 
and UK laboratories as one group. The overall mean is the mean of 
the Italian, Spanish, Portuguese, and UK laboratories. Results of the 
Dutch laboratories were excluded from the calculation of the overall 
mean (to prevent unbalanced data due to the large number of labo-
ratories in comparison to the other countries). For the figures, the 
model of the IFCC Task Force on HbA1c was used [16].
Calculations at aggregated level
To summarize the performance of all 17 analytes in one number, 
the median TE/TAE ratio was calculated: TE/TAE ratio = {Σ(TE/
TAEminimum)}/17 in which TAEminimum is the TAE for the respective 17 ana-
lytes at the minimum performance level.
Results
Analyte level
TE’s for country and manufacturer groups are summa-
rized in Table  3. The underlying bias (B) and between- 
laboratory CV (CVm) are listed in Supplemental Tables  1 
(for countries) and 2 (for manufacturers). Colors indicate 
whether the TEs met one of the TAE specifications for 
optimum (yellow), desirable (gray), minimum perfor-
mance (amber), or not (white). Yellow, gray and amber 
can also be read as gold, silver, and bronze performance. 
It can be seen that for sodium (Na), none of the countries 
and manufacturers even met the minimum specification 
(thus all white). For glucose, all countries and manufac-
turers met one of the specifications: gold (one manufac-
turer), silver (two countries; three manufacturers), and 
bronze (four countries; two manufacturers). Table 3 
shows all numerical TEs; however, when none of the 
specifications are met, the degree and source (bias and 
imprecision component) of TE cannot be readily identi-
fied. These issues are addressed in Figure 1A and B, with 
results for total protein enlarged as an example. The TAE 
for minimum performance of total protein is 5.6% (see 
Table 1). According to TE = B+2CVm, a TE of 5.6% can be 
achieved either with a B of 5.6% and a CVm of 0.0% or (the 
other extreme) with a B of 0.0% and a CVm of 2.8%. These 
extremes are plotted in the figure: a B of 5.6% on the y-axis 
and a CVm of 2.8% on the x-axis. Similarly, the extremes for 
desirable and optimum performance were calculated (B’s 
of 3.7 and 1.8%; CVm’s of 1.8 and 0.9%). The extremes on 
both axes are the limits of triangles for a golden optimum, 
a silver desirable, and a bronze minimum performance. 
The TEs of the countries (left side) and manufacturers 
(right side) are visualized by plotting the respective B’s 
and CVm’s (taken from Supplemental Tables 1 and 2). For 
total protein, it can be seen that of the countries, only UK 
(U; red) met the minimum specification. The manufac-
turer graph shows that Siemens Dimension (D; brown), 
Siemens Vista (S; purple) and Beckman-Coulter Olympus 
AU (O; green) were within the minimum specifications. 
Abbott (A; red) and Roche (R; yellow) were moderately 
outside, and Beckman-Coulter UniCel DxC (B; blue) was 
far outside the specifications. The performance of all 
the other analytes are visualized with respect to country 
and manufacturer. The enzymes in Table 3 and Figure 1 
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Table 3: Total error (%) and TE/TAE ratio per country and per manufacturer.
Analyte   Countries 
 
Manufacturers
ES  IT  PT  UK  All  NL Abb  Oly  Bec  Roc  SAd  SDi
K   5.4  5.8  7.6  5.1  6.1  4.7  7.8  6.3  3.3  4.1  4.4  7.1
Na   4.1  3.3  4.9  2.8  3.9  3.2  4.0  4.0  3.1  3.2  1.9  4.2
Cl   5.1  4.3  5.0  5.1  5.1  4.0  3.9  4.7  3.4  4.4  5.1  6.1
Ca   7.1  6.3  7.3  5.4  6.3  5.2  6.4  7.0  6.5  4.5  7.2  8.5
Mg   9.7  12  12  8.2  11  7.2  9.9  8.5  26  7.1  10  13
Uric acid   14  14  11  7.4  12  10  6.8  5.5  4.4  9.2  5.5  17
Glucose   7.7  6.8  8.3  8.0  7.5  6.7  7.1  8.7  2.9  6.8  4.9  6.3
Total protein  7.2  7.9  8.5  5.0  7.3  6.4  6.6  5.2  11  8.0  4.8  4.5
Cholesterol   10  7.1  7.2  7.1  7.9  7.5  5.9  10  5.0  4.9  5.3  7.5
HDL-Chol   12  13  14  13  13  12  19  10  12  9.7  14  13
Amylasea   13  19  24  23  21  9.3  23  32  11  14  14  –
ASATa   16  7.0  24  29  27  10  33  18  32  28  22  18
ALATa   29  26  38  29  31  8.1  29  20  39  32  25  25
CKa   18  16  21  9.2  16  11  9.3  19  –  16  13  11
GGTa   22  24  21  11  21  10  16  11  –  22  13  22
APa   25  31  27  20  27  16  31  15  33  16  17  18
LDa   11  14  17  11  16  8.4  15  27  11  10  11  4.2
TE/TAE ratio   0.7  0.7  0.9  0.8  1.0  0.6  1.1  0.8  0.7  0.7  0.6  0.7
aFor enzymes, the data of IFCC traceable laboratories. Amber (bronze), meets minimum criterion; Gray (silver), meets desirable criterion; 
Yellow (gold), meets optimum criterion; Abb, Abbott Architect; Oly, Beckman-Coulter Olympus; Bec, Beckman-Coulter UniCel DxC; Roc, 
Roche; SAd, Siemens Advia; SDi, Siemens Dimension; TE/TAE ratio, median ratio (TE/TAE minimum) of all analytes.
are from laboratories using methods claimed to be trace-
able to the respective IFCC RMPs only. The percentages of 
(excluded) laboratories not reporting in units traceable to 
the IFCC RMPs are provided in Table 4.
Aggregated level
Results can also be reviewed at a higher aggregation 
level. Especially when a new analytical platform is con-
sidered, it is convenient to describe the performance as 
one number, rather than numbers for each of the ana-
lytes. The performance of a platform is expressed as 
the median TE/TAE ratio of the 17 analytes. When the 
observed TE of an analyte and TAE at the minimum per-
formance level of that analyte are equal, the TE/TAE 
ratio is 1.0. At the ratio of 1.0, that analyte just meets 
the minimum performance specification. The higher the 
TE/TAE ratio, the worse the performance. The median 
TE/TAE ratio of the 17 analytes is an overall estimate of 
performance. Median TE/TAE ratios are shown in Table 
3 (bottom line; detailed calculations in Supplemental 
Table 3) and are visualized in Figure 2. For comparison, 
the ratios of three analytes (Na, Ca, and CK) are also 
included in Figure 2. It can be seen that there is little 
difference in performance between countries or between 
manufacturers. For Na and Ca, the ratio is high, and for 
CK, the ratio is low in all countries and for all manu-
facturers. This also applies for the median ratio with 
all values within the minimum or just within the desir-
able performance specifications. Figure 2 also shows 
the overall ratio (irrespective of country and manufac-
turer) as an estimate of the analytical performance of 
the respective analytes: the minimum, desirable, and 
optimum performance specifications are met by 8, 2, 
and 1 analytes, respectively. Six analytes did not meet 
any of these specifications.
Discussion
In this study, we aimed to estimate the analytical per-
formance of 17 general chemistry analytes in European 
medical laboratories. The design of the study reflected 
this aim: (a) commutable samples with target values 
assigned with RMPs, (b) input from five countries, (c) 
inclusion of analytical platforms from the major manu-
facturers, (d) sound data derived from the mean of six 
samples, and (e) clear performance specifications derived 
from BV data. This approach is in line with the outcome of 
the 2014 European Federation of Clinical Chemistry and 
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Figure 1: Performance per country and per manufacturer.
For each of the analytes, bias (y-axis) and between laboratory CV (x-axis) are plotted for countries on the left (I, blue = Italy; N, purple = the 
Netherlands; P, green = Portugal; U, red = United Kingdom; S, yellow = Spain) and manufacturers on the right (A, red = Abbott Architect; 
B, blue = Beckman Coulter UniCel DxC; O, green = Beckman Coulter Olympus AU; R, yellow = Roche Cobas; S, purple = Siemens Advia; D, 
brown = Siemens Dimension). Specifications for minimum, desirable, and optimum performance are indicated by the amber, gray, and 
yellow triangles, respectively.
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Figure 1 (continued)
Laboratory Medicine (EFLM) strategic conference on ana-
lytical performance specifications in laboratory medicine 
[17]. Results were not evaluated at the level of individual 
laboratories. This paper focuses on aggregated data: for 
each country and each manufacturer.
Performance at analyte level
Table 3 and Figure 1 clearly demonstrate that the perfor-
mance of the individual analytes K, uric acid, glucose, 
and cholesterol performed satisfactory: the minimum 
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Table 4: Percentage laboratories not reporting enzyme results in units traceable to the IFCC RMP.
Enzyme  
 
Countries 
 
Manufacturers 
 
Meana
ES  IT  PT  UK  NL Abb  Oly  Bec  Roc  Adv  Dim
GGT   16  22  21  2  4  20  5  88  7  0  11  16
CK   11  41  11  10  4  20  11  88  0  12  60  20
ALAT   32  0  16  15  3  27  11  0  17  0  10  14
ASAT   37  0  16  11  2  27  11  0  14  0  20  14
Amylase   31  41  22  30  14  73  25  0  10  0  88  29
LD   24  34  26  37  4  0  44  38  43  38  0  31
AP   28  3  16  10  4  20  21  0  0  25  30  14
Mean   26  20  18  16  5  27  18  31  13  11  30  20
aNL not included. ES, Spain; IT, Italy; PT, Portugal; UK, United Kingdom; NL, Netherlands; Abb, Abbott Architect; Oly, Beckman-Coulter 
Olympus; Bec, Beckman-Coulter UniCel DxC; Roc, Roche Cobas; Adv, Siemens Advia; Dim, Siemens Dimension.
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Figure 2: Overall, country and manufacturer specific TE/TAE ratios.
The TAE/TE ratio is plotted on the y-axis with indication of ratios corresponding to specifications for optimum (yellow), desirable (gray), and 
minimum (amber) performance. Countries (ES, Spain; IT, Italy; PT, Portugal; UK, United Kingdom; NL, Netherlands) and manufacturers (Abb, 
Abbott Architect; Oly, Beckman-Coulter Olympus; Bec, Beckman-Coulter UniCel DxC; Roc, Roche Cobas; Adv, Siemens Advia; Dim, Siemens 
Dimension) are plotted on the x-axis. The median ratio of 17 analytes (red dots) and analyte specific ratios of three analytes (gray; Na, Ca, 
CK) are plotted per country (middle part) and per manufacturer (right part). Gray squares (left part) represent overall ratios for the respective 
analytes (ToPr, total protein; AP, alkaline phosphatase; ASAT, aspartate aminotransferase; HDLc, high-density lipoprotein cholesterol; Amyl, 
amylase; Gluc, glucose; ALAT, alanine aminotransferase; UrAc, uric acid; Chol, cholesterol).
performance specification is met in all countries and 
by all manufacturers. The opposite applies to Na, Cl, 
and Ca: in that none of the countries or manufacturers 
met the minimum specification. For Mg, high-density 
lipoprotein (HDL) cholesterol, and total protein the per-
formance can be considered borderline: in that some 
countries and manufacturers met the specification 
whilst others did not. For the enzymes the situation was 
more complicated in that despite efforts from the IFCC, 
approximately 20% of laboratories used methods that 
were not traceable to the IFCC RMPs. Percentages dif-
fered per enzyme, per country, and per manufacturer 
(Table 4). Non-traceable results were excluded from the 
calculations for Table 3 and Figure 1. The reliability of 
the remaining results for which IFCC-traceability was 
claimed is also questionable. Classification was different 
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per country: traceability was either assumed by the labo-
ratories, or assigned by the EQA organizers based on the 
results (a number of EQA organizers expressed concern 
that that the laboratories had insufficient awareness of 
traceability). This is also confirmed by the fact that the 
between-laboratory CV in Spain, Italy, Portugal and UK 
is approximately double that of the Netherlands where 
strict standardization was implemented as part of a con-
certed awareness and implementation initiative from the 
association of clinical chemists, manufacturers, and the 
EQA organizer [3, 13].
Performance at aggregated level
The horizontal distribution of the red dots in Figure 2 dem-
onstrates that the overall performance in the countries 
and of respective manufacturers is not very different. A 
similar horizontal distribution is seen for the gray dots of 
Na, Ca, and CK (and all other analytes – Na, Ca and CK are 
just an example; see Supplemental Table 3). The TE/TAE 
ratios for Na (3.5) and Ca (1.7) are much higher than 1.0, 
indicating that the minimum performance specification 
for these analytes was not achievable if BV data are used 
to define performance specifications. This applied to all 
countries and to all manufacturers. CK is an example of 
the other extreme where low ratios were observed within 
the desirable or even the optimum performance specifi-
cations for all countries by all manufacturers. The study 
suggests that the analytical performance of general chem-
istry analysers is not related to differences in skills in the 
respective countries and is also not related to analytical 
platform of a specific manufacturer. However, the perfor-
mance and therefore the state of the art for each analyte is 
very different.
Comparison with similar EQA concepts
There are only a few EQA schemes using commutable 
samples, most of them related to the group of Thienpont 
et al. [6–9]. It is worth considering the differences between 
our two approaches in terms of the findings of our schemes 
and the use of slightly different samples.
For many analytes, our findings were comparable, 
e.g. glucose and cholesterol met, quality criteria whereas 
HDL  cholesterol (Abbott) did not [8], neither did calcium 
and total protein meet the criteria [6]. We found that alka-
line phosphatase (AP), alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), and lactate dehy-
drogenase (LD) were not traceable to the respective IFCC 
RMPs. We did not subdivide the transaminases based on 
the way of pyridoxalphosphate activation as previous 
investigations showed that traceability may not be sub-
strate dependent [3].
However, some of our findings differed from the 
Thienpont group. They observed a 3.6% negative bias for 
chloride with the Roche Cobas system [7]. We believe that 
this highlighted a temporary effect on the Roche systems. 
We evidence this on the longitudinal data from the Dutch 
EQA program which has used commutable materials 
since 2005. Data from the years 2012–2015 show that the 
Cobas had a bias of −0.4, −0.6, −2.9, and −0.4% (Roche 
Modular bias is +1.0, +0.6, −1.1, and −0.3%). The “dip” 
seen in 2014 was only temporary and has now disap-
peared. Our data and that of Thienpont’s group may have 
been affected by this. It is possible that other contrast-
ing findings, e.g. uric acid and Mg (Abbott) had a similar 
cause [6].
Although we and Thienpont’s group have both used 
commutable frozen human sera, there are some differ-
ences. We used fresh frozen human sera pools, whereas 
Thienpont et al. used panels of 20 fresh frozen single dona-
tion human sera. We do not know whether this compli-
cates any comparison. The advantage of single donation 
is that assay non-specificity can be more easily detected, 
but a single donation has a maximum volume of approxi-
mately 200 mL and a proportion of each sample has to be 
used for targeting, homogeneity, and stability testing. In 
contrast, large sample pools include the option to recruit 
large numbers of participating laboratories, reissue the 
same pool over long periods, and the ability to test over a 
broader range of analyte concentrations. Furthermore, the 
costs of value assignment with RMPs is relastively lower 
for pools than for small single donations.
In this paper, we have chosen to focus our evalua-
tion on the performance of groups (either manufacturers 
or countries) and not on individual laboratories. Results 
allowed the individual laboratories to evaluate their own 
compliance to analytical performance specifications in 
line with the proposals of the EFLM conference on ana-
lytical quality [17], which is only possible with a category-1 
EQA scheme.
Conclusions
Overall, the analytical performance of 11 of 17 general 
chemistry analytes measured in European medical 
laboratories met the minimum performance specifica-
tions. There were no significant differences between 
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the countries or between manufacturers. There were 
however, major differences between the analytes. There 
are six analytes for which the minimum quality specifi-
cations are not met and manufacturers should strive to 
improve their performance for these analytes. Standardi-
zation of enzyme methods towards IFCC RMPs has not 
been fully achieved and requires ongoing efforts. The 
study demonstrated that it is feasible for national EQA 
organizers to share fresh frozen commutable human sera 
and that retrospective combination of their data reveals a 
pan-European picture of analytical quality.
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